Evidence map›Paper›PMID 39779375›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2025

Amyloid-β-Driven Synaptic Deficits Are Mediated by Synaptic Removal of GluA3-Containing AMPA Receptors.

Niels R Reinders, Sophie J F van der Spek, Remco V Klaassen, Karin J Koymans, Harold D MacGillavry, August B Smit, Helmut W Kessels

Abstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Neurotransmitter Systems in Alzheimer's Disease.Current issues in molecular biology · 2026
    Review
  2. Article
  3. Article
  4. Early involvement of D-serine in β-amyloid-dependent pathophysiology.Cellular and molecular life sciences : CMLS · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Niels R ReindersNetherlands Institute for Neuroscience, Royal Netherlands Academy of Arts and Sciences, Amsterdam 1105 BA, The Netherlands h.w.h.g.kessels@uva.nl n.r.reinders@uu.nl.
Sophie J F van der SpekCenter for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam 1081 HV, The Netherlands.
Remco V KlaassenCenter for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam 1081 HV, The Netherlands.
Karin J KoymansSwammerdam Institute of Life Sciences, Amsterdam Neuroscience, University of Amsterdam, Amsterdam 1098 XH, The Netherlands.ORCID 0000-0001-6519-7658
Harold D MacGillavryDivision of Cell Biology, Neurobiology and Biophysics, Department of Biology, Faculty of Science, Utrecht University, Utrecht 3584 CH, The Netherlands.ORCID 0000-0002-6153-3586
August B SmitCenter for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam 1081 HV, The Netherlands.
Helmut W KesselsNetherlands Institute for Neuroscience, Royal Netherlands Academy of Arts and Sciences, Amsterdam 1105 BA, The Netherlands h.w.h.g.kessels@uva.nl n.r.reinders@uu.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The detrimental effects of oligomeric amyloid-β (Aβ) on synapses are considered the leading cause for cognitive deficits in Alzheimer's disease. However, through which mechanism Aβ oligomers impair synaptic structure and function remains unknown. Here, we used electrophysiology and amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) imaging on mouse and rat neurons to demonstrate that GluA3 expression in neurons lacking GluA3 is sufficient to resensitize their synapses to the damaging effects of Aβ, indicating that GluA3-containing AMPARs at synapses are necessary and sufficient for Aβ to induce synaptic deficits. We found that Aβ oligomers trigger the endocytosis of GluA3 and promote its translocation toward endolysosomal compartments for degradation. Mechanistically, these Aβ-driven effects critically depend on the PDZ-binding motif of GluA3. A single point mutation in the GluA3 PDZ-binding motif prevented Aβ-driven effects and rendered synapses fully resistant to the effects of Aβ. Correspondingly, proteomics on synaptosome fractions from APP/PS1-transgenic mice revealed a selective reduction of GluA3 at an early age. These findings support a model where the endocytosis and lysosomal degradation of GluA3-containing AMPARs are a critical early step in the cascade of events through which Aβ accumulation causes a loss of synapses.

Indexed as

Amyloid beta-PeptidesReceptors, AMPASynapsesAnimalsCells, CulturedEndocytosisHumansMaleMiceMice, Inbred C57BLMice, TransgenicNeuronsRatsAmyloid beta-Peptidesglutamate receptor ionotropic, AMPA 3Receptors, AMPAAlzheimerAMPAamyloidGluA3; PDZ domainsynapse

Identifiers

PMID39779375
PMCPMC11867010

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.